No annual revenue total was found in Tyra Biosciences, Inc.'s SEC filings.
Tyra Biosciences, Inc. (TYRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$95.3 million. As of Jun 30, 2026 it held $353.9 million in cash and investments and $5.6 million in total debt.
Revenue
—
Net income (TTM)
$-148.56M
-40.4% vs year-ago TTM
Operating cash flow (TTM)
$-109.65M
-26.6% vs year-ago TTM
Free cash flow (TTM)
$-109.90M
-26.7% vs year-ago TTM
EPS (TTM)
$-2.40
-34.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
53.87M
+1.5% vs prior year
Net cash
$348.36M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TYRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1863127
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M |
| Diluted EPS | -$2.01 | -$1.51 | -$1.62 | -$1.32 | — |
| Operating cash flow | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M |
| Stockholders' equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M |
| Cash and investments | $256.0M | $341.4M | $203.5M | $251.2M | $302.2M |
| Total debt | $5.8M | $6.2M | $6.5M | $2.6M | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 426 Tyra Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.